arrow
Y

Yongjie Xie

Tianjin Medical University
H指数:12
被引数:488

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer

靶向TNK2/ACK1逆转免疫抑制性肿瘤微环境,并与胰腺癌的免疫化疗产生协同作用

2025-12-060
OA
CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway

CLT-003通过阻断PI3K/AKT/HIF-1α通路在胰腺癌中发挥抗肿瘤活性。

2025-09-010
PRE
Corrigendum to “A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis” [Drug Resist. Updates 81 (2025) 101252]

勘误:“一种新型的铂(IV)前药,gramine-Pt(IV)通过激活cGAS-STING并调节TGF-β-MHC-I轴来增强化疗免疫疗法” [Drug Resist. Updates 81 (2025) 101252]

2025-06-130
PRE
The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma

ESE3/EHF的核浓缩物在胰腺导管腺癌中诱导细胞衰老,而不伴随相关的炎症分泌表型。

2025-02-010
PRE
Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2D Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy

硝夫替莫靶向ESE3/EHF抑制CXCR2D中性粒细胞浸润并克服胰腺癌对化疗和免疫疗法的耐药性

2024-07-013
PRE
Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress

RUNX1抑制剂联合吉西他滨通过调节BiP/PERK/eif2α 轴介导的内质网应激减轻胰腺导管腺癌的化疗耐药性

2023-09-114
OAAI